KRW 5130.0
(-1.35%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | -6.95 Billion KRW | 77.95% |
2022 | -31.52 Billion KRW | 21.26% |
2021 | -40.03 Billion KRW | -203.09% |
2020 | -13.21 Billion KRW | -272.49% |
2019 | 7.65 Billion KRW | 57.37% |
2018 | 4.86 Billion KRW | -76.56% |
2017 | 20.76 Billion KRW | 5291.92% |
2016 | 385.12 Million KRW | 118.74% |
2015 | -2.05 Billion KRW | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q2 | -11.27 Billion KRW | -929.12% |
2024 Q1 | 1.37 Billion KRW | 119.71% |
2023 Q2 | 1.28 Billion KRW | 111.61% |
2023 FY | -6.95 Billion KRW | 77.95% |
2023 Q4 | -6.95 Billion KRW | 56.57% |
2023 Q3 | -16 Billion KRW | -1349.34% |
2023 Q1 | -11.03 Billion KRW | 65.0% |
2022 Q2 | -48.12 Billion KRW | -43.68% |
2022 FY | -31.52 Billion KRW | 21.26% |
2022 Q4 | -31.52 Billion KRW | 53.13% |
2022 Q3 | -67.26 Billion KRW | -39.76% |
2022 Q1 | -33.49 Billion KRW | 16.34% |
2021 Q4 | -40.03 Billion KRW | -76.61% |
2021 Q2 | -21.54 Billion KRW | -37.04% |
2021 Q1 | -15.71 Billion KRW | -18.17% |
2021 FY | -40.03 Billion KRW | -203.09% |
2021 Q3 | -22.67 Billion KRW | -5.24% |
2020 Q3 | -10.8 Billion KRW | -226.86% |
2020 Q1 | 4.58 Billion KRW | -24.41% |
2020 FY | -13.21 Billion KRW | -272.49% |
2020 Q2 | -3.3 Billion KRW | -172.17% |
2020 Q4 | -13.3 Billion KRW | -23.06% |
2019 Q3 | 2.49 Billion KRW | 0.0% |
2019 FY | 7.65 Billion KRW | 57.37% |
2019 Q4 | 6.06 Billion KRW | 143.28% |
2019 Q1 | 8.63 Billion KRW | 77.47% |
2018 Q4 | 4.86 Billion KRW | 0.0% |
2018 FY | 4.86 Billion KRW | -76.56% |
2017 FY | 20.76 Billion KRW | 5291.92% |
2016 FY | 385.12 Million KRW | 118.74% |
2015 FY | -2.05 Billion KRW | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
Osang Healthcare Co.,Ltd | -108.91 Billion KRW | 93.618% |
InBody Co.,Ltd | -16.2 Billion KRW | 57.105% |
Curexo Inc. | -15.03 Billion KRW | 53.757% |
Seegene, Inc. | -48.57 Billion KRW | 85.69% |
i-SENS, Inc. | 98.45 Billion KRW | 107.06% |
Ray Co., Ltd. | 67.09 Billion KRW | 110.361% |
Gencurix Inc. | 15.02 Billion KRW | 146.265% |
L&C Bio Co., Ltd | 67.18 Billion KRW | 110.347% |